Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

TG Therapeutics stock

TGTX
US88322Q1085
A1JXW7

Price

22.38
Today +/-
-0.41
Today %
-1.99 %
P

TG Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the TG Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the TG Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the TG Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze TG Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

TG Therapeutics Stock Price History

DateTG Therapeutics Price
10/2/202422.38 undefined
10/1/202422.83 undefined
9/30/202423.39 undefined
9/27/202423.83 undefined
9/26/202423.33 undefined
9/25/202423.35 undefined
9/24/202423.31 undefined
9/23/202423.25 undefined
9/20/202424.65 undefined
9/19/202425.28 undefined
9/18/202425.25 undefined
9/17/202425.08 undefined
9/16/202424.89 undefined
9/13/202423.73 undefined
9/12/202423.19 undefined
9/11/202423.07 undefined
9/10/202423.53 undefined
9/9/202423.75 undefined
9/6/202422.03 undefined
9/5/202421.46 undefined

TG Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into TG Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by TG Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects TG Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of TG Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into TG Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing TG Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on TG Therapeutics’s growth potential.

TG Therapeutics Revenue, EBIT and net profit per share

DateTG Therapeutics RevenueTG Therapeutics EBITTG Therapeutics Net Income
2029e1.5 B undefined0 undefined710.62 M undefined
2028e1.32 B undefined675.65 M undefined605.61 M undefined
2027e1.04 B undefined477.05 M undefined400.32 M undefined
2026e719.19 M undefined199.53 M undefined242.93 M undefined
2025e505.05 M undefined106.81 M undefined119.23 M undefined
2024e334.94 M undefined-5.72 M undefined23.29 M undefined
2023233.66 M undefined20.63 M undefined12.67 M undefined
20222.79 M undefined-192.84 M undefined-198.34 M undefined
20216.69 M undefined-344.77 M undefined-348.1 M undefined
2020150,000 undefined-273.59 M undefined-279.38 M undefined
2019150,000 undefined-169.06 M undefined-172.87 M undefined
2018150,000 undefined-174.4 M undefined-173.48 M undefined
2017150,000 undefined-118.71 M undefined-118.48 M undefined
2016150,000 undefined-78.97 M undefined-78.25 M undefined
2015150,000 undefined-63.18 M undefined-62.95 M undefined
2014150,000 undefined-55.72 M undefined-55.78 M undefined
2013150,000 undefined-20.17 M undefined-20.48 M undefined
201220,000 undefined-25.8 M undefined-18.07 M undefined
20110 undefined-880,000 undefined-850,000 undefined
20100 undefined-2.02 M undefined620,000 undefined
20090 undefined-1.77 M undefined-2.79 M undefined
20080 undefined-4.41 M undefined-4.27 M undefined
20070 undefined-12.14 M undefined-12.03 M undefined
20060 undefined-10 M undefined-9.69 M undefined
20050 undefined-7.47 M undefined-19.32 M undefined
20040 undefined-6.14 M undefined-6.48 M undefined

TG Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000000000000.0100.230.330.510.721.041.321.5
---------------------66.6711,550.0043.3551.2042.3844.7826.8013.64
-------------------83.33100.0093.99------
000000000000000000052219000000
-1-3-6-7-10-12-4-1-20-25-20-55-63-78-118-174-169-273-344-19220-51061994776750
--------------------5,733.33-9,600.008.58-1.5020.9927.6845.8251.14-
-1-6-6-19-9-12-4-200-18-20-55-62-78-118-173-172-279-348-1981223119242400605710
-500.00-216.67-52.6333.33-66.67-50.00---11.11175.0012.7325.8151.2846.61-0.5862.2124.73-43.10-106.0691.67417.39103.3665.2951.2517.36
00.010.010.020.020.020.030.030.042.1713.1125.4134.0745.6549.0462.0775.4788.37115.33132.22135.41148.51000000
----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The TG Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the TG Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                           
1.77.85.410.830.70.100.59.716.540.578.877.244.984.768.8140.4605.4314.8161.7217.51
000000000.200000000001.4051.09
0000000000000000000000
00000000000000000000039.82
0000.20.30.20.70.10.10.121.76.49.55.98.510.18.76.314.86.69.52
1.77.85.4113.30.90.80.10.89.818.542.285.286.750.893.278.9149.1611.7331168.3317.94
000.10.10.10000000002.42.72.511.811.811.110.89.56
000000000004.90250000035.512.40
00000030010000000000000000
0000000017.73.92.800000000000
000000000800800800800800800800800800800800800799
000.10.10.10.1000000.10.70.80.70.61.21.31.31.31.31.29
000.20.20.20.10.30.117.74.73.65.81.526.63.94.14.513.913.948.725.311.64
1.77.85.611.23.511.10.218.514.522.14886.7113.354.797.383.4163625.6379.7193.6329.59
                                           
0001001001001001001000000100100100100100100100100151
00.010.020.040.040.050.050.060.060.010.030.080.180.260.270.420.550.741.51.571.591.67
-1.1-7.5-14-33.3-43-55-59.3-61.9-61.3-0.9-18.9-39.4-95.2-158.1-236.4-354.9-528.3-701.2-980.6-1,328.7-1,527-1,514.36
003000000000000000000000
0000000000000000000000
0.76.84.49.61.5-0.9-4.4-6.7-5.49.615.640.380.3101.936.167.224.338.9519.5237.358.8160.74
0.30.51.11.61.41.30.50.20.20.71.14.849.315.325.936.4303751.34238.47
00.40.100.60.60.90.30.50.10.30.70.70.81.41.82.35.410.111.61013.62
00000000.80.800.20.20.20.20.20.20.248.817.31.51.21.63
0.8000000.101.70000000000000
00000001.20.10.90.70.70.30.20.10.10.10.223.1100
1.10.91.21.621.91.52.53.31.72.36.45.210.517283984.487.565.453.253.72
0000001.20.616.13.32.50.100000297.766.871.1100.12
0000000000000000000000
000000344.601.81.71.51.422.420.7111110.310.615.25
0000004.24.620.73.34.31.81.51.422.420.74018.777.181.7115.37
1.10.91.21.621.95.77.12456.68.26.711.91930.459.7124.4106.2142.5134.9169.08
1.87.75.611.23.511.30.418.614.622.248.587113.855.197.684163.3625.7379.8193.7329.82
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of TG Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand TG Therapeutics's financial health and stability.

Assets

TG Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that TG Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of TG Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into TG Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-1-5-5-19-9-12-4-200-26-20-55-62-78-118-173-172-279-348-19812
0000000000000000000000
0000000000000000000000
000100000004-52882725-19-12-1-84
020111112-2023104731153229251641254278
0000000000000000004358
0000000000000000000000
0-3-5-6-7-10-4-1-10-5-10-35-44-61-93-128-132-214-295-176-31
0000000000000000000000
00-430000000-4-18-2426-810-240-20-50
00-431000000-4-18-2426-810-240-20-50
0000000000000000000000
0000001000000000029040025
193120700291239696851331131756792047
2831107301911396868513311320467941072
0000002000000000000-100
0000000000000000000000
15-68-6-20009624150-3031-1470440-254-196-9
-0.77-3.46-5.83-6.29-7.79-10.24-4.45-1.05-1.97-0.09-5.19-10.75-35.08-44.73-61.93-93.76-129.02-132.94-214.87-296.03-176.18-31.41
0000000000000000000000

TG Therapeutics stock margins

The TG Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of TG Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for TG Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the TG Therapeutics's sales revenue. A higher gross margin percentage indicates that the TG Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the TG Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the TG Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the TG Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the TG Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the TG Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

TG Therapeutics Margin History

TG Therapeutics Gross marginTG Therapeutics Profit marginTG Therapeutics EBIT marginTG Therapeutics Profit margin
2029e93.95 %0 %47.34 %
2028e93.95 %51.19 %45.88 %
2027e93.95 %45.83 %38.46 %
2026e93.95 %27.74 %33.78 %
2025e93.95 %21.15 %23.61 %
2024e93.95 %-1.71 %6.95 %
202393.95 %8.83 %5.42 %
202290.32 %-6,911.83 %-7,108.96 %
202188.19 %-5,153.51 %-5,203.29 %
202093.95 %-182,393.32 %-186,253.33 %
201993.95 %-112,706.67 %-115,246.66 %
201893.95 %-116,266.66 %-115,653.32 %
201793.95 %-79,140 %-78,986.66 %
201693.95 %-52,646.67 %-52,166.66 %
201593.95 %-42,120 %-41,966.67 %
201493.95 %-37,146.67 %-37,186.66 %
201393.95 %-13,446.67 %-13,653.33 %
201293.95 %-129,000 %-90,350 %
201193.95 %0 %0 %
201093.95 %0 %0 %
200993.95 %0 %0 %
200893.95 %0 %0 %
200793.95 %0 %0 %
200693.95 %0 %0 %
200593.95 %0 %0 %
200493.95 %0 %0 %

TG Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The TG Therapeutics earnings per share therefore indicates how much revenue TG Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue TG Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates TG Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of TG Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating TG Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

TG Therapeutics Revenue, EBIT and net profit per share

DateTG Therapeutics Sales per ShareTG Therapeutics EBIT per shareTG Therapeutics Earnings per Share
2029e9.7 undefined0 undefined4.59 undefined
2028e8.53 undefined0 undefined3.91 undefined
2027e6.72 undefined0 undefined2.59 undefined
2026e4.65 undefined0 undefined1.57 undefined
2025e3.26 undefined0 undefined0.77 undefined
2024e2.16 undefined0 undefined0.15 undefined
20231.57 undefined0.14 undefined0.09 undefined
20220.02 undefined-1.42 undefined-1.46 undefined
20210.05 undefined-2.61 undefined-2.63 undefined
20200 undefined-2.37 undefined-2.42 undefined
20190 undefined-1.91 undefined-1.96 undefined
20180 undefined-2.31 undefined-2.3 undefined
20170 undefined-1.91 undefined-1.91 undefined
20160 undefined-1.61 undefined-1.6 undefined
20150 undefined-1.38 undefined-1.38 undefined
20140 undefined-1.64 undefined-1.64 undefined
20130.01 undefined-0.79 undefined-0.81 undefined
20120 undefined-1.97 undefined-1.38 undefined
20110 undefined-0.41 undefined-0.39 undefined
20100 undefined-50.5 undefined15.5 undefined
20090 undefined-59 undefined-93 undefined
20080 undefined-147 undefined-142.33 undefined
20070 undefined-607 undefined-601.5 undefined
20060 undefined-500 undefined-484.5 undefined
20050 undefined-373.5 undefined-966 undefined
20040 undefined-614 undefined-648 undefined

TG Therapeutics business model

TG Therapeutics Inc is a biopharmaceutical company based in New York City, USA. The company was founded in 2012 and focuses on the development and commercialization of innovative therapy options for various types of cancer and autoimmune diseases. TG Therapeutics was founded as a result of a collaboration between Michael S. Weiss, an experienced investment banker and biotechnology manager, and Laurence N. Charous, an oncologist and clinical researcher. The company has roots in two predecessor companies: Manhattan Pharmaceuticals and LFB Biotechnologies. Both had failed, and TG rose from their remains. TG Therapeutics' business model is to develop a new therapy option by combining drugs of different drug classes that target the needs of patients with specific cancer conditions. The dual blockade approach, which simultaneously inhibits various signaling pathways that sustain tumor cells, is particularly promising. TG Therapeutics operates a diversified portfolio strategy and has several drug candidates in different stages of development for numerous cancer conditions, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' main products for cancer treatments currently are umapalisib and umbralisib, both of which are PI3K delta inhibitors and are being developed for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia. TG-1101 (Ublituximab) is a CD20-targeted antibody therapy used in lymphomas and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' research and development efforts are driven by an experienced team of oncologists and scientists, including CEO Michael S. Weiss. The company maintains close relationships with academic institutions and research facilities. TG Therapeutics holds a broad patent portfolio covering technologies and compounds that can be used in cancer and autoimmune disease treatment. In 2020, TG Therapeutics' revenue reached approximately $109 million, compared to $14 million in the previous year. This increase in revenue was due to the sales of umbralisib. However, the company has not yet received FDA approval for any of its drugs in the US. TG Therapeutics expects that the future success of the company will be based on the clinical activity of its pipeline, market acceptance of its products, and successful completion of studies and regulatory approvals. As of December 31, 2020, TG Therapeutics had 248 employees. The company's leading body, the board of directors, consists of an experienced team of executives and advisors, including Chairman and CEO Michael S. Weiss, CFO Sean A. Power, CMO Adam D. Feuerstein, and COO Scott T. Smith. TG Therapeutics has had a tumultuous past, but the company can now look forward to a promising pipeline and a very strong financial position. The research and development of this biopharmaceutical company are promising, and it remains to be seen which of the research products will actually break through and be introduced to the market. TG Therapeutics is one of the most popular companies on Eulerpool.com.

TG Therapeutics SWOT Analysis

Strengths

1. Strong Pipeline: TG Therapeutics Inc maintains a robust pipeline of potential therapeutics, demonstrating their dedication to research and development.

2. Innovative Approach: The company adopts innovative approaches to develop novel therapies, contributing to their competitive advantage in the pharmaceutical industry.

3. Experienced Team: TG Therapeutics Inc is supported by a highly skilled and experienced management team, allowing for effective decision-making and strategic planning.

Weaknesses

1. Dependence on Key Products: The company's success heavily relies on the performance of a few key products in their portfolio. Any setbacks or regulatory issues concerning these products could negatively impact their financial stability.

2. Limited Market Presence: TG Therapeutics Inc may face challenges in establishing a strong market presence, as they operate in a highly competitive industry dominated by larger pharmaceutical companies.

3. Financial Constraints: The company's financial resources may limit their ability to fully explore and develop certain research opportunities, potentially hindering their growth and innovation.

Opportunities

1. Growing Demand for Innovative Therapies: The increasing demand for groundbreaking therapies presents TG Therapeutics Inc with an opportunity to capitalize on their innovative drug candidates and gain a significant market share.

2. Strategic Partnerships: Collaborating with established pharmaceutical companies or research institutions can provide TG Therapeutics Inc with additional resources, expertise, and opportunities for expansion.

3. Mergers and Acquisitions: The company could explore potential mergers or acquisitions to enhance their product portfolio, accelerate development timelines, or access new markets.

Threats

1. Stringent Regulatory Environment: The pharmaceutical industry is subject to strict regulations, which may delay or impede TG Therapeutics Inc's product development process, leading to increased costs and potential market entry barriers.

2. Patent Expirations: The expiration of key patents for competitor products may increase market competition and affect the pricing and demand for TG Therapeutics Inc's offerings.

3. Clinical Trial Risks: The company faces the inherent risks associated with clinical trials, such as unexpected adverse events or failure to demonstrate efficacy, which could negatively impact their reputation and financial performance.

TG Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

TG Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

TG Therapeutics shares outstanding

The number of shares was TG Therapeutics in 2023 — This indicates how many shares 148.508 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue TG Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates TG Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of TG Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating TG Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

TG Therapeutics stock splits

In TG Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for TG Therapeutics.

TG Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.05 0.04  (185.84 %)2024 Q2
3/31/2024-0.04 -0.07  (-92.31 %)2024 Q1
12/31/2023-0.11 -0.1  (6.02 %)2023 Q4
9/30/20230.12 0.73  (518.64 %)2023 Q3
6/30/2023-0.25 -0.34  (-34.02 %)2023 Q2
3/31/2023-0.37 -0.28  (25.23 %)2023 Q1
12/31/2022-0.27 -0.39  (-47.06 %)2022 Q4
9/30/2022-0.35 -0.26  (25.35 %)2022 Q3
6/30/2022-0.52 -0.3  (42.33 %)2022 Q2
3/31/2022-0.61 -0.51  (15.87 %)2022 Q1
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the TG Therapeutics stock

Eulerpool World ESG Rating (EESG©)

39/ 100

🌱 Environment

36

👫 Social

48

🏛️ Governance

32

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

TG Therapeutics shareholders

%
Name
Stocks
Change
Date
8.81172 % The Vanguard Group, Inc.13,642,307199,77012/31/2023
8.12229 % Weiss (Michael S)12,574,9291,001,9081/6/2024
5.95530 % BlackRock Institutional Trust Company, N.A.9,219,990728,59612/31/2023
5.33108 % State Street Global Advisors (US)8,253,573-1,564,04912/31/2023
2.61374 % Darwin Global Management Ltd4,046,5984,046,59812/31/2023
2.18657 % Pictet Asset Management Ltd.3,385,2452,564,84212/31/2023
2.02801 % Wellington Management Company, LLP3,139,76443,29012/31/2023
2.00016 % Geode Capital Management, L.L.C.3,096,646162,82012/31/2023
1.89174 % Millennium Management LLC2,928,788912,35712/31/2023
1.43069 % Opaleye Management Inc.2,215,000325,00012/31/2023
1
2
3
4
5
...
10

TG Therapeutics Executives and Management Board

Mr. Michael Weiss57
TG Therapeutics Chairman of the Board, President, Chief Executive Officer (since 2011)
Compensation 10.44 M
Mr. Sean Power41
TG Therapeutics Chief Financial Officer, Treasurer, Corporate Secretary
Compensation 1.97 M
Mr. Laurence Charney76
TG Therapeutics Lead Independent Director
Compensation 437,502
Mr. Kenneth Hoberman58
TG Therapeutics Independent Director
Compensation 397,502
Dr. Yann Echelard59
TG Therapeutics Independent Director
Compensation 395,002
1
2

Most common questions regarding TG Therapeutics

What values and corporate philosophy does TG Therapeutics represent?

TG Therapeutics Inc represents a strong commitment to improving the lives of patients by developing innovative therapies in the field of hematological malignancies and autoimmune diseases. The company's corporate philosophy revolves around scientific excellence, patient-centricity, and collaborative partnerships. With a focus on research and development, TG Therapeutics Inc aims to bring transformative treatments to market that address unmet medical needs. Through its dedication to advancing medical science, this company strives to make a positive impact on the lives of patients, healthcare professionals, and the wider community.

In which countries and regions is TG Therapeutics primarily present?

TG Therapeutics Inc is primarily present in the United States. The company's headquarters are located in New York, and it focuses on the development and commercialization of novel treatments for various B-cell malignancies and autoimmune diseases. TG Therapeutics Inc primarily operates in the United States market, fostering collaborations with healthcare providers, research organizations, and regulatory authorities to advance its innovative therapies. With an unwavering commitment to improving patient outcomes, TG Therapeutics Inc continues to drive its presence and impact within the United States' healthcare landscape.

What significant milestones has the company TG Therapeutics achieved?

TG Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones. Most notably, the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for its innovative therapy, umbralisib, in combination with ublituximab, for the treatment of adult patients with marginal zone lymphoma (MZL) and follicular lymphoma (FL). This approval marks a major breakthrough in the field of oncology and reinforces TG Therapeutics Inc's commitment to developing effective treatments for hematologic malignancies. Additionally, the company has successfully completed various clinical trials, demonstrating the potential of its pipeline to address unmet medical needs.

What is the history and background of the company TG Therapeutics?

TG Therapeutics Inc is a renowned biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases. Established in 1993, TG Therapeutics has emerged as a key player in the pharmaceutical industry, committed to advancing medical breakthroughs. With a focus on developing targeted therapies, the company has achieved significant milestones in its history. Over the years, TG Therapeutics has successfully introduced novel drugs and treatment options, catering to unmet medical needs. Their dedication to research and development, coupled with a strong commitment to patient care, has positioned TG Therapeutics Inc as a leading name in the healthcare sector.

Who are the main competitors of TG Therapeutics in the market?

The main competitors of TG Therapeutics Inc in the market include pharmaceutical companies such as AbbVie Inc., Roche Holding AG, and Johnson & Johnson. These companies operate in similar therapeutic areas and have a strong presence in the market. TG Therapeutics Inc faces competition in the development and commercialization of therapies for various conditions, such as lymphoma and chronic lymphocytic leukemia.

In which industries is TG Therapeutics primarily active?

TG Therapeutics Inc is primarily active in the biotechnology and healthcare industries.

What is the business model of TG Therapeutics?

The business model of TG Therapeutics Inc revolves around the development and commercialization of innovative biopharmaceutical products. Specializing in the field of oncology and B-cell malignancies, TG Therapeutics focuses on creating novel therapies to address the unmet medical needs of patients. By harnessing its expertise in research and development, the company aims to discover and develop targeted therapies that can improve the outcome and quality of life for individuals battling certain types of cancer. Through strategic partnerships, clinical trials, and regulatory initiatives, TG Therapeutics Inc strives to bring next-generation treatments to market, ultimately benefiting both patients and shareholders.

What is the P/E ratio of TG Therapeutics 2024?

The TG Therapeutics P/E ratio is 142.69.

What is the P/S ratio of TG Therapeutics 2024?

The TG Therapeutics P/S ratio is 9.92.

What is the AlleAktien quality score of TG Therapeutics?

The AlleAktien quality score for TG Therapeutics is 4/10.

What is the revenue of TG Therapeutics 2024?

The expected TG Therapeutics revenue is 334.94 M USD.

How high is the profit of TG Therapeutics 2024?

The expected TG Therapeutics profit is 23.29 M USD.

What is the business model of TG Therapeutics

TG Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapies for cancer and autoimmune diseases. The company's business model includes the development of new drugs and their marketing. The company is divided into various divisions, each focused on specific therapy areas. These divisions include both cancer therapies and immunotherapies used in autoimmune diseases. Each division is led by highly qualified researchers specialized in researching specific types of cancer and autoimmune diseases and collaborate closely to discover advanced technologies. TG Therapeutics' flagship product is the BTK inhibitor Umbralisib, used in various cancers such as lymphomas or leukemias. This drug is a particularly potent molecule specifically developed for its effect on B lymphocytes. By inhibiting these cells, the division of cancer cells is inhibited, stopping the growth of tumor cells. The medication has great potential in treating cancer patients who do not respond to other therapies. In the field of immunotherapy, the company is developing products such as Ublituximab, used in the treatment of autoimmune diseases such as multiple sclerosis. This drug inhibits the activation of B cells, reducing excessive immune reactions in patients. This leads to a decrease in the number of relapses or symptoms of autoimmune diseases and slows down the progression of the disease. TG Therapeutics follows a business-to-business model, forming partnerships with other companies to market its products. However, the company also has extensive sales and marketing capabilities to sell its products directly to hospitals and medical facilities. There is a particular focus on multiple markets, especially in the USA, Europe, and Asia. The company generates revenue through product sales and partnerships with other biotech companies. These partnerships include research agreements and licensing agreements, where the company licenses its technologies and products to other firms for fees. Thus, TG Therapeutics generates income from various revenue streams and is able to continue its research and development and expand its business. In summary, TG Therapeutics' business model is focused on the development of innovative therapies for cancer and autoimmune diseases. Through the close collaboration between researchers and developers, the company has developed a range of therapies that can be used to treat various diseases. The company aims to market its products globally to maximize its success and increase its value for patients and investors.

What is the TG Therapeutics dividend?

TG Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does TG Therapeutics pay dividends?

The dividend cannot currently be calculated for TG Therapeutics or the company does not pay out a dividend.

What is the TG Therapeutics ISIN?

The ISIN of TG Therapeutics is US88322Q1085.

What is the TG Therapeutics WKN?

The WKN of TG Therapeutics is A1JXW7.

What is the TG Therapeutics ticker?

The ticker of TG Therapeutics is TGTX.

How much dividend does TG Therapeutics pay?

Over the past 12 months, TG Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TG Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of TG Therapeutics?

The current dividend yield of TG Therapeutics is .

When does TG Therapeutics pay dividends?

TG Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TG Therapeutics?

TG Therapeutics paid dividends every year for the past 0 years.

What is the dividend of TG Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is TG Therapeutics located?

TG Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von TG Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TG Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did TG Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of TG Therapeutics in the year 2023?

In the year 2023, TG Therapeutics distributed 0 USD as dividends.

In which currency does TG Therapeutics pay out the dividend?

The dividends of TG Therapeutics are distributed in USD.

All fundamentals about TG Therapeutics

Our stock analysis for TG Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of TG Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.